C ANCER-BEARING patients are known to show decreased circulatory immune function but, in an immunologically tolerant state, they lack only the tumor-specific immune response. 9 It is thus important in cancer immunotherapy to determine tumorspecific immune response, as well as the general immunological competence. On the other hand, because lymphocytes in some cancer patients are stimulated by tumor cells in vitro, 2"4"8 mixed lymphocyte-tumor cell reaction (MLTR) would seem to reveal the level of the host's specific immunoreaction to tumor cells.
To determine the specific immune response, MLTR was performed using peripheral blood lymphocytes (PBL's) and tumor-infiltrating lymphocytes (TIL's) from patients with malignant brain tumors. The effects of lymphokines such as interferon-3, (IFN-3,) and interleukin-2 (IL-2) on MLTR were also evaluated.
Materials and Methods
Blood samples were taken from 12 patients with malignant glioma and six with metastatic brain tumor, ranging in age from 18 to 73 years (mean 42.7 years), who were treated while inpatients at the Department of Neurosurgery, Niigata University. All were newly diagnosed cases with no disease progression. The 12 patients with malignant glioma were histologically diagnosed as having grade III astrocytoma according to World Health Organization classification. ~ Peripheral blood lymphocytes were obtained from these patients before operation or other therapy. The Karnofsky scores of the patients were over 60%, and all of the patients are still alive. The six patients with metastatic brain tumor were histologically diagnosed as having primary lung cancer and, although they complained of slight headache and motor weakness, their disease was stable at the time of study. Blood samples were taken prior to any surgery or other therapy for brain tumors or primary lung cancer. In addition, PBL's were obtained from six healthy individuals in the same age range.
A tumor tissue block obtained at surgery was minced as soon as possible and made into a single-cell suspension with RPMI-1640 culture medium. The suspension was allowed to stand in a 750-ml Falcon culture flask for 24 hours. The nonadhesive cell suspension was then rinsed with RPMI-1640 culture medium and separated into TIL's and tumor cells by Ficoll-Hypaque discontinuous concentration gradient centrifugation. 6 The pu- Mixed lymphocyte-tumor cell reaction was performed using the lymphocytes and the tumor cells. The PBL's and TIL's, adjusted to 5 x 105/ml, were used as responders. Tumor cells were inactivated by adding mitomycin C (25 ug/ml), allowed to stand for 30 minutes at 37~ and rinsed three times with RPMI-1640 culture medium. The suspensions were adjusted to 1 x 104/ml for use as stimulators. For MLTR, 1 ml of the stimulators and 1 ml of the responders were placed in a 10-ml Falcon culture tube for 6 days in a CO2 incubator. The MLTR reached its highest peak on the 6th day of culture. Tritiated thymidine (~H-TdR, 0.5 uCi) was added 16 hours before the end of the reaction because a 16-hour pulse with radioisotope offered the best assessment of ~H-TdR uptake into the reactive lymphocytes. In control experiments, autologous tumor cells, glioma cell (NP-1), Daudi cell, and K-562, as well as the same numbers of identical PBL's, allogeneic PBL's, and phytohemagglutinin P (PHA, 50 tag) were used as stimulators in the same way for comparison with the results of MLTR. The PHA stimulation was best at a concentration of 50 ug/ml. Responding indexes (RI) were calculated by the following formula: RI = (cpm in test MLTR -cpm in stimulators alone treated with mitomycin C) / cpm in lymphocyte culture only.
To study the effects of lymphokines on MLTR, IFN-(500, 1000, or 2000 U) or IL-2 (50, 100, or 200 U) was added to the MLTR system as described in the previous section. To detect the effects of the biological response modifiers on the MLTR, OK-432 (0.5, 1.0, or 2.0 U) was also studied in the same way. After 6 days of culture, the 3H-TdR uptake in the MLTR system was assayed to evaluate the effects of the lymphokines on MLTR. The cells used in the MLTR were not stained with trypan blue, so these preparations were not endotoxic to the MLTR.
Results
The responses of the PBL's from six normal individuals to tumor cells, PHA, and allogeneic PBL's are shown in Table 1 , and the uptake of ~H-TdR into the mitomycin C-treated tumor cells is presented in Table  2 . The MLTR in patients with malignant brain tumors was compared with these data.
One-way MLTR using the patients' PBL's or TIL's as responders and the tumor cells as stimulators caused blastogenesis of the patients' lymphocytes. In the patients with malignant glioma, MLTR using PBL as a responder resulted in RI's of 1.80, 1.2 l, and 1.02, when autologous tumor cells, NP-1, and Daudi cells were used as stimulators, respectively. These values were considerably lower than those evaluated when allogeneic PBL's or PHA were used as an antigenic stimulus, indicating that the antigenic specificity of glioma cells was weak (Table 3) . The fact that all RI's in the experiments with TIL's as a responder were lower than those associated with PBL's suggests that the systemic response reflected directly upon the brain tumor was relatively weak compared with other organs.
On the other hand, stimulation with tumor cells of PBL's from the patients with metastatic brain tumors enhanced the synthesizing ability of the lymphocytes. In this group, RI's in the MLTR using PBL's as responders were 3.52, 1.51, and 1.70, respectively, when the stimulators were autologous tumor cells, Daudi cells, or K-562. These values were slightly higher than those for the glioma patients, but were much lower than the levels of responses to allogeneic PBL's or PHA. Contrary to the results for the glioma group, MLTR with autologous tumor cells as stimulators resulted in higher levels of TIL response compared with PBL (Table 4). Stimulation with the remaining antigens induced stronger responses from PBL's. Because the PBL's of the patients with metastatic brain tumors were stimulated with glioma and other tumor cells, there may be common antigens with cancer cells and glioma cells.
The MLTR results in all 18 cases were compared to detect differences in the systemic and tumor-specific immune responses (Table 5) . Seven (58.3%) of the 12 patients in the glioma group received some antigenic stimulation from autologous tumor cells, showing mitosis and growth of lymphocytes; however, only three (25%) showed RI's of over 2.0 for both PBL's and TIL's, indicating strong tumor-specific immune responses. The MLTR's with TIL's as responders were weaker than those with PBL's, suggesting low levels of tumor-specific immune response.
By contrast, four (66.7%) of the six patients with metastatic brain tumor exhibited strong reactions with RI's of over 2.0 for both PBL's and TIL's. Thus, the responses of TIL's to autologous tumor cells were slightly stronger than those of PBL's. The formula to calculate the RI may not be complete, but we consider it sufficient to detect minor changes in the MLTR. Responding indexes over 2.0 were thought to indicate significantly strong responses.
Interferon-y, OK-432, and IL-2 were added to the reaction system for the samples from the seven patients with malignant tumor (three with glioma and four with metastatic brain tumors) in whom the RI in autologous MLTR was over 2.0. Neither OK-432 nor IL-2 had any effect but, when 500 U of IFN-3, was added, the MLTR was enhanced nearly twofold. However, the MLTR was rather attenuated at higher concentrations. The MLTR enhanced by IFN-~, was further increased by the addition of 200 U of IL-2 alone; the remaining lymphokines exerted no significant effect (Fig. 1) .
Allogeneic mixed lymphocyte cultures were performed using allogeneic PBL's as stimulators, and a strong reaction was observed in 12 patients with malignant brain tumor (eight with glioma and four with metastatic brain tumors). The effects of the biological response modifiers were similar in these patients. Again, OK-432 and IL-2 caused no definite changes, but the addition of IFN-3, enhanced the mixed lymphocyte culture reaction in a concentration-dependent manner * PBL = peripheral blood lymphocyte; TIL = tumor infiltrating lymphocyte. Stimulating cells were treated with mitomycin C. t Mean + SD = mean counts per minute (cpm) -+ standard deviation. RI = responding index (see text).
( Fig. 2) . However, no significant effect on the mixed lymphocyte culture was observed for any of the lymphokine combinations.
Discussion
In treating patients with malignant brain t u m o r by i m m u n o t h e r a p y , it is important to determine their tumor-specific i m m u n e responses. Since the M L T R appears to be an i m m u n e response resembling the antigenrecognizing mechanism that occurs in the first stage of graft rejection, it is useful in detecting antigenic differences between the host and t u m o r and in evaluating host reactivity against the t u m o r ? 57
We performed M L T R studies in patients with malign a n t brain t u m o r to assess their reactivity against tumors. Lymphocyte responses to autologous t u m o r cells were observed in seven (58.3%) of the 12 patients with malignant glioma. This confirmed the presence of imm u n e responses mediated by Class II antigens, a major histocompatible antigen complex, because the recognition of t u m o r antigens by helper T cells is performed with Class II antigens. However, only three (25%) of the 12 patients showed strong responses with RI's of over 2.0 for both PBL's and TIL's; in all three patients, the responses of TIL's were weaker than those of PBL's. Thus, the systemic immune responses reflected upon the tumor tissues were weak, showing the brain to be immunologically specific by the existence of the bloodbrain barrier.
In four of six patients with metastatic brain tumor, RI values were higher than 2.0, and PBL's exhibited stronger responses than TIL's. The remaining two patients showed weak PBL responses but strong TIL responses. The difference in the responses between PBL's and TIL's may result from the depression of helper T cells in the TIL's, or the presence of inhibitory factors in the tumor tissues, although we have no definite data at the present stage.
It was also found that lymphocytes in patients with malignant brain tumor were not necessarily antigenically stimulated by tumor cells. Other authors have pointed out that the host response to tumor is weak in many cases. ~~~ The relationship between the disease stage, the MLTR, and the in vivo antitumoral lymphocyte properties suitable for production of effector cells remains to be investigated. Since the MLTR was enhanced by the addition of IFN-3, in some cases, this lymphokine is likely to intensify the manifestation of Class II antigens. Therefore, a combination of lymphokines may enhance immune responses. OK-432 or IL-2 added independently exerted no effect on MLTR; thus, their effect on nonspecific immunological competence needs to be considered.
These studies suggest that there may be relevance between the level of tumor-specific immune response on the basis of MLTR and the use of immunotherapy with lymphokines. Comparison between systemic and local tumor-specific immune responses may be important.
